Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Market Cap	27.18B
Revenue (ttm)	3.07B
Net Income (ttm)	404.52M
Shares Out	420.73M
EPS (ttm)	0.97
PE Ratio	66.58
Forward PE	35.57
Dividend	0.20 (0.32%)
Ex-Dividend Date	Jun 17, 2025

Volume	11,205,978
Average Volume	12,488,076
Open	61.94
Previous Close	63.31
Day's Range	61.94 - 65.48
52-Week Range	30.43 - 65.58
Beta	0.54
RSI	78.24
Earnings Date	Aug 6, 2025

About Betta Pharmaceuticals

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is based in Hangzhou, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 1,961
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300558

Financial Performance

In 2024, Betta Pharmaceuticals's revenue was 2.89 billion, an increase of 17.74% compared to the previous year's 2.46 billion. Earnings were 402.57 million, an increase of 15.67%.